key: cord-1033501-ho9cz64h
authors: Noris, Marina
title: The case of complement inhibitors
date: 2021-08-19
journal: Adv Biol Regul
DOI: 10.1016/j.jbior.2021.100822
sha: bdea688aa06644020340668bf20f29a3742cb517
doc_id: 1033501
cord_uid: ho9cz64h

Severe COVID-19 is characterized by lung and multiorgan inflammation and coagulation in the presence of overactivation of the complement system. Complement is a double edged-sward in SARS-Cov-2 infection. On one hand, it can control the viral infection in milder cases, on the other hand in cases with severe and prolonged infection massive complement activation occurs, which can intensify lung and systemic inflammation and promote a procoagulant and prothrombotic state. Several uncontrolled studies and controlled clinical trials with different complement inhibitors have been performed and others are ongoing. Results are promising in some but negative in others. Further studies are required to elucidate the benefit to risk profile of complement inhibitors in COVID-19 patients at different stages of the disease and to clarify the best targets in the complement cascade.

The complement system is an integral component of the innate immune response and represents the host's first immune response to clear pathogens 1 . The complement system is organized in three activation pathways: the classical, the lectin and the alternative pathway ( Figure 1 ) and all are triggered in the presence of pathogens including bacteria and viruses. The three pathways converge on the formation of the classical/lectin and the alternative C3 convertases that cleave C3 into C3bthat binds the surface of pathogens leading to virus aggregation and phagocytosis through interaction with complement receptors present on neutrophils and macrophages -and C3a, a potent anaphylatoxin that attracts and activates inflammatory leukocytes 1 . C3b also contributes to the formation of the C5 convertases, which cleave C5 generating C5a, another anaphylatoxin, and C5b that initiates the formation of the terminal membrane attack complex C5b-9 ( Figure 1 ) that inserts into the surface of pathogens and of virus-infected cells and causes lysis. 1 Evidence are accumulating that SARS-CoV-2 activates all the three complement pathways. 2 SARS-CoV interacts with the lectin pathway recognition molecule mannose binding lectin (MBL), and MBL binding to SARS-CoV-infected cells results in enhanced deposition of C4-activation fragments. 2, 3 SARS-CoV-2 nucleocapsid protein binds the MBL associated serine protease MASP-2, and potentiates MBL interaction and lectin pathway. 3 An in vitro study documented that the SARS-CoV-2 spike protein can directly activate the alternative complement pathway at cell surface level. Indeed, the S1 and S2 subunits of spike protein added to normal human serum increased C5b-9 deposition on a human erythroleukemia cell line. This effect was inhibited by a FD inhibitor that blocks the alternative pathway. 4 The classical pathway may be activated in the later phase of infection by virus-specific antibodies and COVID-19-associated autoantibodies 5 , as documented by staining of COVID-19 patient's lung for C1q along with widely distributed IgG staining . 6 Ramlall et al 7 by transcriptional profiling of nasopharyngeal swabs of SARS-CoV-2 infected patients, demonstrated strong transcription of genes encoding proteins of the classical/lectin (C1q, J o u r n a l P r e -p r o o f C4, C2) and alternative (factor B -FB-, C3) pathways. Finally, in a prospective cohort study, the large majority of COVID-19 hospitalized patients showed higher than normal plasma levels of complement activation products of the classical/lectin (C4d) and alternative pathway (C3bBbP, figure 1), as well as of C5a and sC5b-9, indicating systemic activation of the three complement pathways until the terminal common pathway. 8 Notably, in another study, 9 plasma sC5b-9 levels were higher in patients with COVID-19 vs. those with influenza and patients non-COVID-19 respiratory failure, identifying terminal complement activation as a distinctive feature of COVID-

Local complement activation and inflammatory response may effectively contribute to the control of SARS-CoV-2 infection in the first phases of the disease. However unstrained complement activation, as it occurs in the context of intense and prolonged SARS-CoV-2 infections, can be detrimental, contributing to damage of host tissues, and to lung and multi-organ dysfunction .

Immunohistochemical analysis of lungs of patients who died of COVID-19 showed deposits of C1q, C4, C3 and C5b-9 localized in the capillaries of the interalveolar septa, in alveolar epithelial cells as well as in infiltrating leukocytes 6, 10, 11 .

Evaluation of complement circulating parameters revealed a strong association of the degree of complement activationparticularly of the terminal pathway-with disease severity and adverse outcome. In a prospective study, plasma levels of sC5b-9 and C4d were significantly higher in COVID-19 patients with respiratory failure than in patients without such complication 8 , and logistic regression showed an association between sC5b-9 concentrations and odds of respiratory failure. 8 In another cohort, plasma levels of C3a and sC5b-9 were higher in patients in intensive care unit (ICU) as compared with non-ICU patients . 12 Also the plasma levels of the other product of the terminal pathway, C5a, are elevated in COVID-19 patients and were found to be proportional J o u r n a l P r e -p r o o f to disease severity, reaching maximal values in the group developing acute respiratory distress syndrome (ARDS). 11 C5a is a strong chemoattractant that can recruit and activate neutrophils and other myeloid leukocytes at the site of infection, and stimulate the release of reactive oxygen species and neutrophil extracellular traps (NETs) that damage the alveolar epithelium and increase the permeability of alveolar capillaries, causing edema. 3 Excessive production of C5a leads to massive release of cytokines from circulating and infiltrating leukocytes, a phenomenon called cytokine storm . 13 Blood neutrophils and monocytes of patients with COVID-19-associated pneumonia and ARSD express high levels of the C5a receptor (C5aR1), and in vitro exposure to C5a increased the production of the inflammatory cytokines IL-6, TNF alpha and CCl2 by blood monocytes isolated from COVID-19 patients. 11 Consistently, C5a was detected in the broncoalveolar lavage fluid of COVID-19 patients who developed ARSD along with large numbers of neutrophils and monocytes expressing C5aR1, and inflammatory cytokines and chemokines. 11 Altogether these data support a role of C5a as a mediator of the exaggerated inflammatory response and the associated lung injury and dysfunction in severe COVID-19.

Endothelial dysfunction, coagulopathy, thrombotic microangiopathy, and complement activation COVID-19 often manifests with a procoagulant state that associates with disease severity and fatal outcome. 2 It has been estimated that more than 70% of deaths related to COVID-19 are attributed to clotting-associated complications often leading to multiorgan failure. 14 Patients with COVID-19 associated coagulopathy have strongly elevated levels of plasma D-dimer, a fibrin degradation product present in the blood after activation of fibrinolysis 15 . This was already known from the China experience. In a retrospective study of March 2020 on 191 patients from Wuhan, D-dimer levels over 1 microgr/mL at admission predicted an 18-fold increase in the odds of dying 16 .

These findings are consistent with histologic examinations of autoptic tissues from COVID-19 cases that confirmed high incidence of venous thromboembolisms 17 , and microvascular thrombi with endothelial injury and swelling consistent with a thrombotic microangiopathy, in the lungs but also in the heart, liver, small bowel, kidney and other organs 18, 19, 20 . Such complications have been observed also in pediatric population. In a study on 50 hospitalized pediatric patients with acute SARS-CoV-2 infection, 48% met criteria for thrombotic microangiopathy with hemolytic anemia, thrombocytopenia and organ damage mainly in the liver and the kidney 21 .

Evidence is accumulating that complement activation is associated with multi-organ thrombosis in COVID-19 patients. A pattern of microvascular injury and thrombosis with vasculopathy associated with C5b-9 deposition was observed in the lung of 5 patients with severe COVID-19. 10 Vascular C5b-9 deposition was also seen in the skin of patients affected by retiform purpura indicating ischemia of the affected tissue. 10 Analysis of kidney specimens revealed strong C5b-9 staining in peritubular capillaries, in glomerular afferent and efferent arterioles and traces in the glomerular tuft along with fibrin microthrombi occluding glomerular capillaries. 2 Other authors described C1q, C4, C3 and C5b-9 deposits on tubules and vessels of kidneys and on hepatic artery and portal vein of the liver. 6, 22 Cardiac microthrombi from COVID-19-positive autopsy cases showed more fibrin and C5b-9

immunostaining compared with intramyocardial thromboemboli from COVID-19 negative patients with ST-elevation myocardial infarction. 20 Finally, in a study in 197 hospitalized patients with COVID-19, higher baseline plasma concentrations of C3a and sC5b-9 were observed in patients who developed a thromboembolic event, and sC5b-9 concentrations correlated with D-dimer levels. 12 Collectively, available data support a link between complement activation and thrombotic complications of SARS-CoV-2 infection.

Among the several effector molecules generated by complement activation cascade, the terminal products C5a and C5b-9 are the most likely candidates for promoting endothelial perturbation and vascular thrombosis, through multiple processes. 2 C5a increases tissue factor activity on endothelial cells 23 and in the circulation. 24 C5a and the C5b-9 induce the exocytosis of P-selectin and von Willebrand factor multimers (VWF) from endothelial cells 25 that promote platelet adhesion and aggregation, and the shedding of thrombomodulin from cell surface 26 , which triggers the coagulation cascade. C5a also stimulates the production of NETs which contain antimicrobial peptides important to prevent the spread of infections but may also trap platelets and promote coagulopathy and endothelial dysfunction 27 .

Of interest, neutrophils isolated from COVID-19 patients spontaneously release NETs expressing tissue factor. In addition, control neutrophils stimulated with platelet rich plasma (PRP) from COVID-19 patients generate NETs that induce tissue factor expression in human aortic endothelial cells in vitro and both effects were attenuated by C5a receptor blockade. 28 Finally, plasma from severe COVID-19 patients requiring mechanical ventilation activated control neutrophils to release NETs, an effect that was restrained by an anti-C5a neutralizing antibody 29 .

Complement inhibition has been proposed as a potential target in limiting tissue inflammation and thrombotic complications associated with COVID-19 2, 30 , but great care should be taken in choosing between the drugs that are currently available or in advanced clinical development 2, 31, 32 .

Timing is also relevant since shutting down complement activation components that restrict viral propagation may be harmful while preventing uncontrolled activation is desirable 33 .

In this context, C3 inhibitors do not appear to be a safe option for COVID-19 patients, since these drugs will prevent the activation of all three complement pathways in response to viral infections.

Studies to establish the relationship between the protective role of the lectin complement pathway in virus clearance vs. its potential pathogenetic roles in sustaining inflammatory response and tissue J o u r n a l P r e -p r o o f injury will be instrumental in the perspective of clinical studies with specific inhibitors such as anti-MASP2 antibodies 34 , in COVID-19 patients.

On the other hand, C5 inhibitors could exert a favorable effect by blocking the proinflammatory and prothrombotic actions of the terminal products of the complement cascade (C5a and C5b-9) activated by SARS-CoV-2, while preserving the activity of early complement components that are important for viral clearance and activation of the adaptive immune response . 1, 2, 35 Terminal complement inhibition with the anti-C5 monoclonal antibody eculizumab has been shown to be an effective therapeutic tool in thrombotic, hematological and inflammatory diseases. 36 In particular, eculizumab blocked venous thromboembolic events in paroxysmal nocturnal hemoglobinuria and thrombotic microangiopathy in atypical hemolytic uremic syndrome . 36 Thus, C5 inhibition could theoretically also protect COVID-19 patients from complement-mediated lung damage and prevent thromboembolic events. In this context, case report and case series showed positive effects on clinical outcomes in patients with severe COVID-19 treated with eculizumab or other C5 blockers 37, 38, 39 , even in combination with the JAK1/2 inhibitor ruxolitinib 40 .

In a non-randomized proof-of-concept French study 41 (primary end-point) and at day 28 was higher and survival time was prolonged in eculizumab treated patients compared to control patients. 41 In addition, C5 inhibition was associated with faster improvement in the ratio of arterial oxygen tension over fraction of inspired oxygen (PaO2/FiO2), with better renal function and steeper decline in cytokine blood levels. 41 However, total complement activity (CH50) was detectable at day 7 in two third of eculizumab treated patients J o u r n a l P r e -p r o o f indicating that the terminal pathway was not completely inhibited by the drug, even with the intensified regimen. 41 Massive activation of complement and the increased expression of complement components associated with severe and prolonged SARS-CoV-2 infection 3 may have played a role in the insufficient C5 inhibition by eculizumab.

On the other hand, a phase 3 study trial with another anti-C5 antibody, ravulizumab (ClinicalTrials.gov identifier, NCT4369469), in adults with severe COVID-19 requiring mechanical ventilation, has recently halted patient recruitment due to lack of efficacy as revealed by interim analysis (https://ir.alexion.com/news-releases/news-release-details/alexion-provides-update-phase- Blocking C5 activation prevents the formation of both terminal pathway products, C5a and C5b-9, thus exposing the patients to risk of developing infections. In this regard, in the French study, the J o u r n a l P r e -p r o o f eculizumab-treated group experienced more secondary bacterial infections versus the control group. 41 Selective blocking of C5a/C5aR could have advantages over C5 blockade since it preserves the formation of the C5b-9 membrane attack complex, which is crucial to kill pathogens. In addition, this approach will inhibit the C5a-mediated recruitment of inflammatory leukocytes in lung and other organs, 11 and limit the production of pro-thrombotic factors from immune cells, platelets, and endothelium 2, 43, 28, 44, 45 . A proof-of-concept, phase 2 randomized study (first part of the adaptive phase 2/3 PANAMO trial, ClinicalTrials.gov Identifier: NCT04333420) has investigated the effect anti-C5a antibody IFX-1 in 15 adults with severe COVID-19 as compared with 15 controls receiving best supportive care only. 46 The relative change in the PaO2/FiO2 in the supine position between baseline and day 5 (primary outcome) did not differ between treatment groups, although secondary outcome results showed a lower incidence of serious pulmonary embolisms in patients receiving IFX-1 than in the control group. 46 However, the study was not powered on this endpoint and results should be In a preliminary study, the human recombinant C1 esterase inhibitor Conestat alpha (Ruconest) was administered to 5 adult patients with severe COVID-19 pneumonia. 50 Treatment was well-tolerated and rapidly reduced fever, levels of inflammatory markers and oxygen supplementation in 4 patients, only one required mechanical ventilation. All five patients recovered. 50 

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Overview of complement activation and regulation

The case of complement activation in COVID-19 multiorgan impact

A double edged-sword -The Complement System during SARS-CoV-2 infection

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Complement control for COVID-19

Multi-organ complement deposition in COVID-19 patients

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes

The COVID-19 Cytokine Storm

Clotting disorder in severe acute respiratory syndrome coronavirus 2

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation

Endothelial cell infection and endotheliitis in COVID-19

Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study

Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations

Complement Activation in Kidneys of Patients With COVID-19

C5a induces tissue factor activity on endothelial cells

A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways

Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface

Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis

Role of C5a in inflammatory responses

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

Complement as a target in COVID-19?

Therapeutic targeting of the complement system

Clinical promise of next-generation complement therapeutics

COVID-19, microangiopathy, hemostatic activation, and complement

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Complement and viral pathogenesis

Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Complement C5 inhibition in patients with COVID-19 -a promising target

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

The Complement C5a-C5aR1 GPCR Axis in COVID-19

Role of C5a in multiorgan failure during sepsis

Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, openlabel, phase 2 randomised controlled trial

Avacopan for the Treatment of ANCA-Associated Vasculitis

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement